Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Prospective Clinical Trail to Evaluate the Efficacy and Safety of Orelabrutinib Combined With Low-Dose Radiotherapy or Rituximab in the Treatment of Ocular Adnexal MALT Lymphoma

NCT07247383 is registered in ClinicalTrials.gov with Second Affiliated Hospital, Zhejiang University, School of Medicine as lead sponsor.

NCT NCT07247383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07247383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Prospective Clinical Trail to Evaluate the Efficacy and Safety of Orelabrutinib Combined With Low-Dose Radiotherapy or Rituximab in the Treatment of Ocular Adnexal MALT Lymphoma
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 19, 2025
Completion date
December 31, 2028
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

marginal zone lymphoma of ocular adnexal, marginal zone lymphoma(mzl)